Akebia Ther (AKBA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $131.67M
Last updated: Nov 17, 2026 at 11:04 AM ET
Akebia Ther (AKBA) Financials: Revenue, Profit and Cash Flow
Akebia Ther reported revenue of $236.20M for the fiscal year ended Dec 31, 2025, up 47.5% from the year before. That year, net income was -$5.34M with a net margin of -2.3%, operating cash flow was $67.99M and free cash flow was $67.70M. The quarter ended Sep 30, 2026 had revenue of $36.90M and net income of -$14.35M.
Revenue and Margins
The operating margin was 9.9% in the fiscal year ended Dec 2025, the highest of the 7 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $1.53M, a compound annual rate of 75.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $236.20M | +47.5% | 83.3% | 9.9% | -2.3% |
| Dec 2024 | $160.18M | -17.7% | 60.6% | -31.5% | -43.3% |
| Dec 2023 | $194.62M | -33.5% | 61.9% | -23.8% | -26.7% |
| Dec 2022 | $292.48M | +38.2% | 70.7% | -27.6% | -32.2% |
| Dec 2021 | $211.65M | -28.2% | 28.8% | -125.0% | -133.3% |
| Dec 2020 | $294.64M | -12.0% | -0.6% | -128.2% | -130.6% |
| Dec 2019 | $335.00M | +61.3% | 56.6% | -85.5% | -83.5% |
| Dec 2018 | $207.74M | +14.6% | 96.3% | -85.8% | -69.1% |
| Dec 2017 | $181.23M | +11706.3% | 100.0% | -42.3% | -40.7% |
| Dec 2016 | $1.53M | N/A | 100.0% | -8889.9% | -8843.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $236.20M | $160.18M | $194.62M | $292.48M | $211.65M | $294.64M | $335.00M | $207.74M | $181.23M | $1.53M |
| Cost of revenue | $39.46M | $63.18M | $74.15M | $85.57M | $150.67M | $296.48M | $145.34M | $7.77M | $0 | $0 |
| Gross profit | $196.73M | $97.00M | $120.47M | $206.92M | $60.98M | -$1.83M | $189.66M | $199.97M | $181.23M | $1.53M |
| Research and development | $62.36M | $37.65M | $63.08M | $129.99M | $147.85M | $218.49M | $322.97M | $291.01M | $230.89M | $115.78M |
| Operating income | $23.50M | -$50.47M | -$46.26M | -$80.78M | -$264.50M | -$377.83M | -$286.29M | -$178.16M | -$76.67M | -$136.46M |
| Net income | -$5.34M | -$69.41M | -$51.92M | -$94.23M | -$282.02M | -$384.84M | -$279.66M | -$143.59M | -$73.67M | -$135.75M |
| EBITDA | N/A | -$13.20M | -$8.27M | -$40.23M | -$224.13M | -$341.32M | -$249.25M | -$176.89M | -$75.24M | -$135.86M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.90M | $49.13M | $53.54M | $57.62M | $58.77M | $62.47M | $57.34M | $46.50M | $37.43M | $43.65M | $32.61M | $56.20M |
| Gross profit | $30.54M | $38.70M | $41.25M | $45.09M | $49.38M | $52.55M | $49.71M | $26.13M | $23.27M | $26.60M | $21.00M | $37.53M |
| Operating income | -$11.46M | -$6.33M | -$4.70M | -$8.55M | $4.45M | $14.09M | $13.51M | -$14.31M | -$12.51M | -$8.72M | -$14.94M | $1.37M |
| Net income | -$14.35M | -$8.91M | -$9.05M | -$12.24M | $540.00K | $247.00K | $6.11M | -$22.80M | -$20.04M | -$8.58M | -$17.98M | $612.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $48.25M by $136.59M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $376.56M | $220.67M | $241.70M | $356.05M | $529.35M | $644.14M | $771.20M | $996.54M | $364.25M | $300.22M |
| Current assets | $252.96M | $113.83M | $118.15M | $185.18M | $271.15M | $371.44M | $309.53M | $468.27M | $358.36M | $296.32M |
| Cash and equivalents | $184.84M | $51.87M | $42.92M | $90.47M | $149.80M | $228.70M | $147.45M | $104.64M | $70.16M | $187.34M |
| Total liabilities | $343.95M | $269.86M | $272.29M | $350.82M | $455.34M | $396.52M | $376.44M | $360.61M | $241.67M | $232.10M |
| Short-term debt | $0 | $9.71M | $17.50M | $32.00M | $97.54M | $0 | $4.99M | $15.00M | $0 | $9.00K |
| Long-term debt | $48.25M | $38.69M | $17.18M | $34.08M | $0 | $96.38M | $75.81M | N/A | $0 | $5.00K |
| Shareholder equity | $32.61M | -$49.19M | -$30.58M | $5.23M | $74.01M | $247.62M | $394.76M | $635.93M | $122.57M | $68.12M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $342.13M | $349.66M | $362.52M | $376.56M | $364.15M | $345.60M | $310.19M | $220.67M | $207.14M | $220.20M | $225.48M | $241.70M |
| Total liabilities | $321.76M | $324.64M | $335.14M | $343.95M | $322.56M | $316.37M | $285.60M | $269.86M | $257.54M | $253.95M | $252.74M | $272.29M |
| Cash and equivalents | $159.25M | $155.55M | $162.64M | $184.84M | $166.44M | $137.31M | $113.37M | $51.87M | $34.02M | $39.50M | $41.96M | $42.92M |
| Shareholder equity | $20.37M | $25.02M | $27.38M | $32.61M | $41.59M | $29.22M | $24.58M | -$49.19M | -$50.40M | -$33.75M | -$27.26M | -$30.58M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.6% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $67.99M | -$40.66M | -$23.38M | -$73.15M | -$252.97M | -$110.39M | -$257.44M | -$97.49M | -$56.16M | $57.91M |
| Capital expenditures | $291.00K | $33.00K | $0 | $114.00K | $59.00K | $317.00K | $6.66M | $1.61M | $1.62M | $2.66M |
| Free cash flow | $67.70M | -$40.69M | -$23.38M | -$73.27M | -$253.02M | -$110.70M | -$264.10M | -$99.10M | -$57.78M | $55.24M |
| Investing cash flow | -$7.93M | -$33.00K | $0 | -$114.00K | $39.94M | -$40.00M | $211.18M | $36.59M | -$177.26M | $12.71M |
| Financing cash flow | $72.93M | $49.66M | -$25.21M | $14.60M | $133.73M | $231.72M | $88.97M | $96.56M | $116.24M | $66.95M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.33M | $3.52M | -$21.21M | $31.13M | $28.11M | $22.34M | -$13.59M | -$4.47M | -$6.70M | -$10.07M | -$19.43M | -$2.31M |
| Capital expenditures | $706.00K | $1.08M | $62.00K | $70.00K | $77.00K | $126.00K | $18.00K | $2.00K | $2.00K | $29.00K | $0 | $0 |
| Free cash flow | $1.63M | $2.45M | -$21.27M | $31.06M | $28.03M | $22.22M | -$13.61M | -$4.47M | -$6.70M | -$10.10M | -$19.43M | -$2.31M |
Frequently Asked Questions About AKBA
What is Akebia Ther's annual revenue?
Akebia Ther reported revenue of $236.20M for the fiscal year ended Dec 31, 2025.
How fast is Akebia Ther's revenue growing?
Revenue was up 47.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -6.9%.
Is Akebia Ther profitable?
No. Akebia Ther reported net income of -$5.34M for the fiscal year ended Dec 31, 2025, with a net margin of -2.3%.
How much free cash flow does AKBA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $67.99M minus capital expenditures of $291.00K produced free cash flow of $67.70M.
How much debt does Akebia Ther have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $48.25M, short-term debt of $0 and cash and equivalents of $184.84M.
AKBA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors